EQS-Adhoc: PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE AD-HOC RELEASE.

Disclosure of an inside information acc. to Art. 17 Sec. 1 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation - MAR)
 

PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares

Gräfelfing, Germany, September 12, 2024 - The management board of PharmaSGP Holding SE (the “Company”) (ISIN DE000A2P4LJ5 / WKN A2P4LJ) resolved today, with the approval of the supervisory board, utilizing the authorization of the annual general meeting of June 26, 2024, to buy back up to 594,405 shares of the Company (corresponding to up to 4.95% of the Company’s registered share capital (Grundkapital)) by way of a public share repurchase offer for a consideration amounting to EUR 21.45 per share. It is currently intended to redeem the shares so repurchased and decrease the share capital accordingly.

The Company’s two largest shareholders, FUTRUE GmbH that holds approximately 73.6% of the Company’s share capital, and MVH Beteiligungs- und Beratungs-GmbH that holds approximately 7.8% of the Company’s share capital, have irrevocably committed themselves vis-à-vis the Company not to accept the share repurchase offer for all shares directly or indirectly held by them.

The acceptance period will commence on September 13, 2024, 00:00 (CEST), and is expected to terminate on September 26, 2024, 24:00 (CEST). If the shares tendered into the share repurchase offer exceed 594,405, the declarations of acceptance will be considered proportionally, i.e., in a ratio of the 594,405 shares to the aggregate number of shares tendered into the share repurchase offer. Further details on the public share repurchase offer can be found in the offer document, which will be published on the Company’s website (https://www.pharmasgp.com) under the heading “Investor Relations – The share – Share buy-backs – Share buy-back 2024” prior to the commencement of the acceptance period as well as in the German Federal Gazette under www.bundesanzeiger.de.

Contact

PharmaSGP Holding SE
Claudius Krause (cometis AG)
Lochhamer Schlag 1
82166 Gräfelfing
Germany
Phone: +49 611 205855-28
E-Mail: ir@pharmasgp.com

Disclaimer

This release may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. This release is not directed to or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

Neither this release nor its content may be published, dispatched, distributed or disseminated within the United States of America, and in each case neither by means of utilization of any postal service nor by any other means or instruments of business communication between single states or foreign trade or any facilities of a national stock exchange of the United States of America. This includes, among others, submission by fax, electronic post, telex, telephone and the internet. Copies of this release or any other documents related to this release may also not be distributed or submitted to or within the United States of America.

These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States, Germany or any other jurisdiction.

This release contains forward-looking statements. These statements are based on the current views, expectations and assumptions of the management of PharmaSGP Holding SE and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those described in such statements due to, among other things, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations and competition from other companies, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. PharmaSGP Holding SE does not assume any obligations to update any forward-looking statements.

1986351  12-Sep-2024 CET/CEST